Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Villaris Therapeutics Inc. is active in the Biotechnology & Pharmaceuticals technology area with 1 pending office action currently in progress. This action is assigned to 1 distinct examiner, reflecting a focused prosecution docket at the USPTO. The activity is contained within 1 distinct art unit, indicating a specific technical scope for the company's pending application.
OUSPENSKI, ILIA I is the busiest examiner for the portfolio, responsible for 1 busiest examiner pending office action. With only 1 distinct examiner involved, the prosecution path is highly dependent on the individual standards of OUSPENSKI, ILIA I. Practitioners should tailor their strategy to the specific preferences of this examiner to successfully resolve the 1 pending office action. The alignment of 1 distinct examiner with 1 distinct art unit suggests a very specialized technical focus.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OUSPENSKI, ILIA I | 1 | 77.3% | +20.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18336404 | ANTI-CD122 ANTIBODIES AND USES THEREOF | OUSPENSKI, ILIA I | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18336404 | ANTI-CD122 ANTIBODIES AND USES THEREOF | OUSPENSKI, ILIA I | 1644 | §112 | Non-Final OA | — | Pending | Jun 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVillaris Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ilia I Ouspenski has the most, with 1 of Villaris Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
